AstraZeneca equity cheque gives Summit $2bn ahead of FDA ruling on ivonescimab

Summit Therapeutics has taken in $2.0bn from AstraZeneca through an equity investment, the company said as it published third-quarter and nine-month 2026 results on 4 November. The money arrived after the quarter closed, so it is not in the reported figures. Summit ended September with $629.8m in cash and investments, which means the new funds are more than three times that amount.

The timing is notable. The US Food and Drug Administration has given 14 November 2026 as its goal date for finishing its review of Summit's biologics licence application for ivonescimab. The filing seeks approval for the drug combined with chemotherapy in patients with EGFR-mutated non-squamous non-small cell lung cancer whose disease has progressed after treatment with a tyrosine kinase inhibitor.

Summit's own summary flags a significant hurdle. The agency has told the company it needs to see a survival benefit that meets the test of statistical significance in this patient group, whereas the HARMONi trial did not clear that bar for overall survival in its primary analysis. How the FDA weighs that gap is the main open question for the application.

Summit also disclosed new studies in bladder and kidney cancer, pointing to ambitions beyond lung cancer. It noted that Phase III trials run by Akeso in China showed a significant overall survival benefit. The company's summary does not explain how, if at all, those results bear on the US filing, and the available information does not say what Summit plans to do with the AstraZeneca funds.